Sanofi bags 'breakthrough' tag for new Genzyme rare disease med

Sanofi's ($SNY) rare disease-focused unit Genzyme picked up the FDA's coveted breakthrough-therapy designation for a drug designed to treat a form of Niemann-Pick disease. The French drugmaker is set for a speedy approval decision on the drug, olipudase alfa, an enzyme-replacement treatment. More from FierceBiotech